ENDRA Life Sciences to effect 1-for-20 reverse stock split on Dec 9, 2022

ENDRA Life Sciences Inc.

Stockholders approved the 1-for-20 reverse split at a special meeting on November 29, 2022.
Effective 12:01 a.m. ET Dec 9; every 20 outstanding shares become 1 share; fractional shares rounded up.
Authorized shares remain 80M; exercise price and share counts for outstanding options proportionally adjusted.
Common stock will trade on Nasdaq on a split-adjusted basis under symbol NDRA; new CUSIP 29273B302.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ENDRA Life Sciences Inc.: Effected a 1-for-20 reverse stock split of common stock through a Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation (effective 2022-12-09).

Change: charter amendment
Effective: 2022-12-09

Exact text from the filing

On December 8, 2022, ENDRA Life Sciences Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (Eastern time) on December 9, 2022 (the “Reverse Stock Split”).

View on SEC.gov

Browse all governance changes →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-016272

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.